PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2010-11-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT00408954
- Locations
- πΈπ°
Pfizer Investigational Site, Trencin, Slovakia
Study for Evaluating Different Methods of Measuring Depression Treatment Response
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 165
- Registration Number
- NCT00406952
- Locations
- πΊπΈ
Pfizer Investigational Site, Midvale, Utah, United States
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2012-04-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 83
- Registration Number
- NCT00404495
- Locations
- π¬π§
Pfizer Investigational Site, Sutton, United Kingdom
The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms
- Conditions
- Vasomotor Symptoms
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2011-10-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT00401245
- Locations
Pfizer Investigational Site
Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Serum Bactericidal Activity Assay Development
- Conditions
- Healthy Subjects
- Interventions
- Procedure: Blood Collection
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 955
- Registration Number
- NCT00401232
- Locations
- πΊπΈ
Frontage Clinical Services Inc, Hackensack, New Jersey, United States
πΊπΈSNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
Open-label Extension Study Of RN624
- Conditions
- OsteoarthritisOA Knee PainArthritis
- Interventions
- Drug: RN624 (PF-04383119)
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 287
- Registration Number
- NCT00399490
- Locations
- πΊπΈ
Sports Medicine and Orthopaedics Center, Greensboro, North Carolina, United States
πΊπΈOffice of Walter F. Chase, MD, PA, Austin, Texas, United States
πΊπΈNorthwest Indiana Center for Clinical Research, Merrillville, Indiana, United States
Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.
- Conditions
- Obesity
- Interventions
- Drug: CP-945,598 Treatment BDrug: CP-945,598 Treatment ADrug: Placebo
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1253
- Registration Number
- NCT00396448
- Locations
- π¬π§
Pfizer Investigational Site, Northwood, Middlesex, United Kingdom
Safety Study In Patients Who Were Born Small And Short And Were Treated With Growth Hormone To Achieve Normal Height
- Conditions
- Infant, Small for Gestational Age
- Interventions
- Other: post GH treatment observational study
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00396474
Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 316
- Registration Number
- NCT00396097
- Locations
- πΊπΈ
Central Ohio Pediatric Endocrinology/Diabetes Services (COPEDS), Columbus, Ohio, United States
πΊπΈChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
πΊπΈCooks Children Medical Center/Dept. of Pediatric Endocrinology, Fort Worth, Texas, United States
A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain
- Conditions
- Osteoarthritis
- Interventions
- Drug: placeboDrug: RN624 (PF-04383119)
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2009-10-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 450
- Registration Number
- NCT00394563
- Locations
- πΊπΈ
Pfizer Investigational Site, Yakima, Washington, United States